Title:Guest-host Relationship of Cyclodextrin and its Pharmacological Benefits
Volume: 29
Issue: 36
Author(s): Fatmah Alshati, Teejan Ameer Abed Alahmed, Farheen Sami, Md. Sajid Ali, Shahnaz Majeed, Sheikh Murtuja, M Saquib Hasnain and Mohammed Tahir Ansari*
Affiliation:
- School of Pharmacy, University of
Nottingham Malaysia, Jalan Broga, Semenyih 43500, Selangor, Malaysia
Keywords:
Beta-cyclodextrin, anticancer drugs, PFASs, anti-tubercular drugs, solid dispersion, drug delivery.
Abstract: Many methods, including solid dispersion, micellization, and inclusion complexes, have been employed
to increase the solubility of potent drugs. Beta-cyclodextrin (βCD) is a cyclic oligosaccharide consisting
of seven glucopyranoside molecules, and is a widely used polymer for formulating soluble inclusion complexes
of hydrophobic drugs. The enzymatic activity of Glycosyltransferase or α-amylase converts starch or
its derivatives into a mixture of cyclodextrins. The βCD units are characterized by α -(1-4) glucopyranose
bonds. Cyclodextrins possess certain properties that make them very distinctive because of their toroidal or
truncated cage-like supramolecular configurations with multiple hydroxyl groups at each end. This allowed
them to encapsulate hydrophobic compounds by forming inclusion complexes without losing their solubility
in water. Chemical modifications and newer derivatives, such as methylated βCD, more soluble hydroxyl propyl
methyl βCD, and sodium salts of sulfobutylether-βCD, known as dexolve® or captisol®, have envisaged
the use of CDs in various pharmaceutical, medical, and cosmetic industries. The successful inclusion of drug
complexes has demonstrated improved solubility, bioavailability, drug resistance reduction, targeting, and
penetration across skin and brain tissues. This review encompasses the current applications of β-CDs in improving
the disease outcomes of antimicrobials and antifungals as well as anticancer and anti-tubercular
drugs.
